Acinetobacter baumannii NDM-1 (CDC & FDA AR Isolate Bank #0088), Lung Infection Model, CFU Data

ITEM 608802

CONTACT FOR PRICING

STATUS Available

CONTACT CUSTOMER SERVICE

^{ADD TO FAVORITES}

^{ADD TO PANEL}

OVERVIEW

DOCUMENTS/REFERENCES

RELATED SERVICES

RELATED PRODUCTS

BIOLOGICAL INFORMATION

BACKGROUND INFORMATION

This model assesses the antimicrobial efficacy of test articles in a lung infection model with carbapenem-resistant A. baumannii. Microbial counts in the lung tissue are measured. This carbapenem-resistant A. baumannii strain produces aac(3)-IIe, NDM-1, OXA-64, tet(B), strA and sul2 beta-lactamases. It is resistant to beta-lactam antibiotics, aminoglycosides, and quinolones. It is susceptible to colistin. The CDC & FDA Antimicrobial Resistance Isolate Bank supplied this strain.

SPECIES

Acinetobacter baumannii

STRAIN COMMON NAME

(#0088)

ORGANISM

Gram-negative Bacteria

INCUBATION CONDITIONS

Aerobic

NOTABLE ANTIBIOTIC RESISTANCE GENE

NDM-1

ANTIBIOTIC RESISTANCE GENES

aac(3)-Iie,aac(6')-Ian,ABAF,ADC-26,ant(3")-Iia,aph(3')-VI,aph(6)-Id,ble-MBL,NDM-1,OXA-64,strA,sul2,tet(B)

SOURCE

STRAIN SOURCE

CDC & FDA AR Isolate Bank

STRAIN SOURCE ID

AR Bank #0088

ASSAY INFORMATION

ASSAY TYPE

In Vivo

TESTING INFORMATION

PROCEDURE SUMMARY

Groups of 5 female specific-pathogen-free ICR (CD-1) neutropenic mice are intranasally inoculated with pathogen suspension. Test articles and vehicle are administered per the specification of the study design after inoculation. Doses may be delivered by IV, IV infusion, SC, PO, IM, or IP administration. At 26 hours after infection, animals are humanely euthanized and tissue is aseptically harvested. The collected tissues are homogenized and pathogen counts are determined by agar plating.

CRITERIA FOR SIGNIFICANCE

A significant (p < 0.05) decrease in the bacterial counts of the treated animals compared to the vehicle control group or the baseline control group was considered a significant difference.

TURNAROUND TIME

STANDARD

30 Days

CLINICAL RELEVANCE

THERAPEUTIC AREA

Infectious Disease

ADDITIONAL INFORMATION

BRAND

PDS

TESTING LOCATION

Taiwan - Taipei

OTHER INFORMATION

We will readily accommodate client-specified alterations. These studies are performed at our AAALAC accredited BSL-2 laboratory in Taipei, Taiwan. All aspects of this work are performed in general accordance with the Guide for the Care and Use of laboratory animals (National Academy Press, Washington, DC, 2011). The study protocol was approved by the Pharmacology Discovery Services IACUC and is performed with the oversight of veterinarians to assure the humane treatment of laboratory animals.